

App. No. 10/523,588
Docket No. EX03-057C-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of Francis-Lang, *et al.*

Application No.: 10/523,588

Filed: February 4, 2005

For: CSNK1GS AS MODIFIERS OF THE P21
PATHWAY AND METHODS OF USE

Confirmation No.: 4379

Attorney Docket No.: EX03-057C-US

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.56

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

The GENESEQ® database was queried to identify sequences that are identical or related to the sequences recited in the claims of the above-referenced patent application. The following patent publications were identified:


WO200164905, MILLENNIUM PHARM INC, 2001-09-07
WO200166594, SUGEN INC, 2001-09-13
WO200153493, LEXICON GENETICS INC, 2001-07-26

The above-references have not been reviewed to assess whether they are material to the patentability of the claimed invention; nor have they been reviewed to assess whether they are substantively cumulative to the disclosures of the references cited in and provided with the "Information Disclosure Statement by Applicant" filed simultaneously herewith.

Upon request, Applicants will gladly obtain copies of any of these references and forward them to the Examiner for consideration.

Respectfully submitted,

Dated: March 21, 2005


Laleh Shayesteh Reg. No. 47,937
Tel: (650) 837-8223; Fax: (650) 837-8234

App. No. 10/523,588
Docket No. EX03-057C-US

Rec'd PTO 24 MAR 2005

#5

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of Francis-Lang, *et al.*

Application No.: 10/523,588

Filed: February 4, 2005

For: CSNK1GS AS MODIFIERS OF THE P21
PATHWAY AND METHODS OF USE

Confirmation No.: 4379

Attorney Docket No.: EX03-057C-US

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

In accordance with 37 CFR §1.56, this Information Disclosure Statement is being submitted for the above-referenced application.

Applicant notes that Citation Nos. 17 through 19 of the Information Disclosure Statement in the attached PTO Form 1449 was first cited in the International Search Report (copy attached) from the International Searching Authority in the counterpart PCT application.


In accordance with §1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined by 37 CFR §1.56 exists.


In accordance with §1.97(h), the disclosure contained herein is not intended to constitute an admission that any patent, publication, or other information referred to is "prior art" or "analogous art" for this invention.

It is believed that no fees are required, as the disclosure is delivered within three months of the date of entry of the national stage. However, the Commissioner is authorized to charge any required fees, to deposit account no. 50-1108.

Respectfully submitted,

Dated: March 21, 2005


Laleh Shayanesh Reg. No. 47,937
Tel: (650) 837-8223; Fax: (650) 837-8234



Rec'd PCT/PTO 24 MAR 2005

PTO/SB/08b(08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	10/523,588
Filing Date	02-04-2005
First Named Inventor	Francis-Lang
Art Unit	
Examiner Name	
Attorney Docket Number	EX03-057C-US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	Guo,L., et al., Homo sapiens casein kinase 1, gamma 1 (CSNK1G1), transcript variant 2, mRNA. Genbank identifier no: GI:11545750	✓
	2	Strausberg,R. Homo sapiens, casein kinase 1, gamma 1, clone MGC:19461 IMAGE:4123494, mRNA, complete cds. Genbank GI:16878051	
	3	Kawabata,A., et al., Homo sapiens cDNA: FLJ23304 fis, clone HEP11377. Genbank GI:10439939	✓
	4	Ansorge,W., et al, Homo sapiens mRNA; cDNA DKFZp547K1617 (from clone DKFZp547K1617). Genbank GI:21733126	✓
	5	Guo,L., et al. Homo sapiens casein kinase I gamma 1 isoform mRNA, complete cds. Genbank GI:27375099	
	6	Mishra,S.K., et al. Homo sapiens casein kinase 1, gamma 2 (CSNK1G2), mRNA. Genbank GI:21314777	
	7	Strausberg RL, et al. Homo sapiens casein kinase 1, gamma 2, mRNA (cDNA clone MGC:9354 IMAGE:3851613), complete cds. Genbank GI:18088089	✓
	8	Kitabayashi,A.N.,et al. Homo sapiens casein kinase I gamma 2 primary transcript, complete cds. Genbank GI:2199528	✓
	9	Andersson,B., et al. Homo sapiens clone CDABP0048 mRNA sequence. Genbank GI:9956036	✓
	10	Kusuda,J., et al. Homo sapiens casein kinase 1, gamma 3 (CSNK1G3), mRNA. Genbank GI:4758079	
	11	Kusuda,J., et al. Homo sapiens casein kinase I gamma 3L (CSNK1G3L) mRNA, complete cds. Genbank GI:4590041	


Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Rec'd PCT/PTO 24 MAR 2005

PTO/SB/08b(08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	10/523,588
Filing Date	02-04-2005
First Named Inventor	Francis-Lang
Art Unit	
Examiner Name	
Attorney Docket Number	EX03-057C-US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	12	Strausberg, R.L., et al. Homo sapiens casein kinase 1, gamma 3, mRNA (cDNA clone MGC:48323 IMAGE:4817058), complete cds. Genbank GI:28837292	✓
	13	Guo, L., et al. casein kinase 1, gamma 1 isoform S [Homo sapiens]. Genbank GI:11545751	✓
	14	Kitabayashi, A.N., et al. casein kinase 1, gamma 2 [Homo sapiens]. Genbank GI:5579454	✓
	15	Mishra, S.K., et al. casein kinase 1, gamma 2 [Homo sapiens]. Genbank GI:21314778	✓
	16	Kusuda, J., et al. casein kinase 1, gamma 3 [Homo sapiens]. Genbank GI:4758080	✓
	17	Kusuda J, Hirai M, Tanuma R, Hashimoto K. Cloning, expression analysis and chromosome mapping of human casein kinase 1 gamma1 (CSNK1G1): identification of two types of cDNA encoding the kinase protein associated with heterologous carboxy-terminal sequences. Cytogenet Cell Genet. 2000;90(3-4):298-302.	
	18	Kitabayashi AN, Kusuda J, Hirai M, Hashimoto K. Cloning and chromosomal mapping of human casein kinase I gamma 2 (CSNK1G2). Genomics. 1997 Nov 15;46(1):133-7.	
	19	Zhai L, Graves PR, Robinson LC, Italiano M, Culbertson MR, Rowles J, Cobb MH, DePaoli-Roach AA, Roach PJ. Casein kinase I gamma subfamily. Molecular cloning, expression, and characterization of three mammalian isoforms and complementation of defects in the Saccharomyces cerevisiae YCK genes. J Biol Chem. 1995 May 26;270(21):12717-24.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.